文献速递糖尿病

意义未明的克隆性造血(CHIP)与2型糖尿病发病风险

Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Incident Type 2 Diabetes Risk.
PubMed 文献 · Diabetes Care · 2023-01-01

在TOPMed前瞻性队列中分析17,637名无既往2型糖尿病、心血管疾病或癌症的参与者,基线CHIP患病率为6.0%(n=1,055)。平均随访9.8年间2,467例新发2型糖尿病,CHIP携带者2型糖尿病风险较无CHIP者高23%(CI 1.04, 1.45),TET2和ASXL1突变与风险升高相关。

要点

  • CHIP携带者2型糖尿病风险较无CHIP者高23%(CI 1.04, 1.45)。
  • TET2突变(HR 1.48;CI 1.05, 2.08)和ASXL1突变(HR 1.76;CI 1.03, 2.99)与2型糖尿病风险升高相关。
  • DNMT3A突变与2型糖尿病风险无显著关联(HR 1.15;CI 0.93, 1.43)。

核心结论

  • CHIP与2型糖尿病发病率升高相关。
  • 位于冠心病和死亡相关基因上的CHIP突变也与2型糖尿病相关,提示共享的衰老相关病理。

研究设计与样本

  • 研究基于美国国家心肺血液研究所TOPMed前瞻性队列中6个队列的全基因组测序血液DNA数据。
  • 共纳入17,637名无既往2型糖尿病、心血管疾病或癌症的参与者。
  • 采用多变量校正的风险比(HR)和95%CI,校正年龄、性别、BMI、吸烟、饮酒、教育、自报种族/民族,并通过固定效应Meta分析合并各队列估计值。

主要发现

  • 参与者平均(SD)年龄63.4(11.5)岁,76%为女性,基线CHIP患病率为6.0%(n=1,055)。
  • 平均随访9.8年间,2,467例被诊断为2型糖尿病。
  • CHIP携带者2型糖尿病风险较无CHIP者高23%(CI 1.04, 1.45)。
  • TET2突变者2型糖尿病风险升高(HR 1.48;CI 1.05, 2.08),ASXL1突变者风险升高(HR 1.76;CI 1.03, 2.99)。
  • DNMT3A突变与2型糖尿病风险无显著关联(HR 1.15;CI 0.93, 1.43)。

局限性

  • JAK2和TP53分析的统计效能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Clonal hematopoiesis of indeterminate potential (CHIP) is an aging-related accumulation of somatic mutations in hematopoietic stem cells, leading to clonal expansion. CHIP presence has been implicated in atherosclerotic coronary heart disease (CHD) and all-cause mortality, but its association with incident type 2 diabetes (T2D) is unknown. We hypothesized that CHIP is associated with elevated risk of T2D. RESEARCH DESIGN AND METHODS: CHIP was derived from whole-genome sequencing of blood DNA in the National Heart, Lung, and Blood Institute Trans-Omics for Precision Medicine (TOPMed) prospective cohorts. We performed analysis for 17,637 participants from six cohorts, without prior T2D, cardiovascular disease, or cancer. We evaluated baseline CHIP versus no CHIP prevalence with incident T2D, including associations with DNMT3A, TET2, ASXL1, JAK2, and TP53 variants. We estimated multivariable-adjusted hazard ratios (HRs) and 95% CIs with adjustment for age, sex, BMI, smoking, alcohol, education, self-reported race/ethnicity, and combined cohorts' estimates via fixed-effects meta-analysis. RESULTS: Mean (SD) age was 63.4 (11.5) years, 76% were female, and CHIP prevalence was 6.0% (n = 1,055) at baseline. T2D was diagnosed in n = 2,467 over mean follow-up of 9.8 years. Participants with CHIP had 23% (CI 1.04, 1.45) higher risk of T2D than those with no CHIP. Specifically, higher risk was for TET2 (HR 1.48; CI 1.05, 2.08) and ASXL1 (HR 1.76; CI 1.03, 2.99) mutations; DNMT3A was nonsignificant (HR 1.15; CI 0.93, 1.43). Statistical power was limited for JAK2 and TP53 analyses. CONCLUSIONS: CHIP was associated with higher incidence of T2D. CHIP mutations located on genes implicated in CHD and mortality were also related to T2D, suggesting shared aging-related pathology.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Tobias DK, Manning AK, Wessel J, et al. Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Incident Type 2 Diabetes Risk. Diabetes Care. 2023. PMID: 37756531. doi:10.2337/dc23-0805

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。